RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 143.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 143.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 143.00K |
| SG&A Expenses | 1.26M | 1.26M | -- | -- | 1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.74M | 1.74M | -- | -- | 1.84M |
| Operating Income | -1.74M | -1.74M | -- | -- | -1.70M |
| Income Before Tax | -2.86M | -2.86M | -- | -- | -1.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.86M | -2.86M | -- | -- | -1.47M |
| Earnings from Discontinued Operations | -190.50K | -190.50K | -- | -- | -599.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.05M | -3.05M | -- | -- | -2.07M |
| EBIT | -1.74M | -1.74M | -- | -- | -1.70M |
| EBITDA | -1.67M | -1.67M | -- | -- | -1.61M |
| EPS Basic | -- | -11.46K | -11.46K | -11.46K | -11.46K |
| Normalized Basic EPS | -- | -- | -- | -- | -0.51 |
| EPS Diluted | -- | -11.46K | -11.46K | -11.46K | -11.46K |
| Normalized Diluted EPS | -- | -- | -- | -- | -0.51 |
| Average Basic Shares Outstanding | -- | -- | 3.16M | -- | 1.80M |
| Average Diluted Shares Outstanding | 300.00 | 300.00 | 300.00 | 100.00 | 100.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |